AnaBios Scientific Director Najah Abi-Gerges, PhD, will present “Adult Human Primary Cardiomyocyotes: An Integrative Translational Model for Cardiotoxicity Assessment” on Thursday, November 2, from 11am-12pm EDT. Drug-induced irregular heart beat (pro arrhythmia) and/or changes in contractility (inotropic liability) can limit the utility of potential novel therapeutics. Since abnormal ventricular repolarization can cause not only electrical disorders, but also affect the heart’s contractile function, the main motivation of this study was to develop a new model based on adult human primary cardiomyocytes to provide a preclinical tool for the simultaneous prediction of drug-induced inotropic and pro-arrhythmia risks. To facilitate the scalability of the model to high throughput methodologies, AnaBios recorded fractional sarcomere shortening (SS) using a digital, cell geometry measurement system (IonOptix™) and then record changes in the contractility transients to infer both inotropic (SS) as well as pro-arrhythmia risk (aftercontraction (AC), contractility escape and time to 90% relaxation). To address the clinical relevance of this approach, we performed a validation study in which we assessed the effects of a set of reference drugs with known clinical outcomes. Both positive and negative controls were selected, including 23 torsadogenic and 10 non-torsadogenic drugs.

To attend this Safety Pharmacology Society webinar, please register here.